Patrys Ltd receives $250,000 funding to support brain cancer research

Patrys Ltd (ASX:PAB) will be one of the recipients of a $250,000 grant award to the Telethon Kids Institute from the Cure Brain Cancer Foundation’s inaugural Clinical Accelerator fund.

The funding will support research into the potential therapeutic applications of Patrys’ PAT-DX1 and PATDX3 deoxymabs in the treatment and management of brain cancers.

Patrys’ deoxymabs have already demonstrated promising activity against brain cancers in several animal models, due to their ability to both cross the blood-brain barrier, which few other antibodies are able to achieve, and to block DNA damage repair. (DDR) in cancer cells.

Patrys CEO and Managing Director, Dr James Campbell, said: “This is one of our most exciting collaborations to date. Professor Johns and his team are leaders in translational brain cancer research in Australia and have many international connections. We gratefully acknowledge the Cure Brain Cancer Foundation’s Clinical Accelerator, a visionary program aimed at accelerating potentially transformative therapies for brain cancer patients into the clinic.

“This is the first time this program has been offered and we are honored to be part of the successful inaugural application. We look forward to growing our relationship with the Cure Brain Cancer Foundation, and we look forward to expanding our connections with clinicians and Australian brain cancer researchers as we move towards our Phase 1 clinical trial scheduled for mid-2023.”

The Telethon Kids Institute, based at Perth Children’s Hospital, is one of Australia’s largest and most successful medical research institutes.

The research program will be led by Professor Terrance Johns, Professor of Pediatric Cancer Research and Director of the Kids Cancer Center Telethon, who has a strong background in translational research with extensive national and international networks.

Professor Johns is also co-director of the Australian Brain Cancer Research Alliance (ABCARA), an Australia-wide consortium of researchers and clinicians dedicated to ensuring that promising therapeutic discoveries are translated into the clinic for the treatment of patients with brain cancer.

Professor Terrance Johns said: “This partnership between Telethon Kids and Patrys is a tremendous opportunity to make a difference for brain cancer patients. Advances in new treatments have stalled for more than 30 years; therefore, patient survival barely improved during this period. Our approach represents a radically new strategy for the treatment of brain cancer. We believe this could significantly improve the effectiveness of current treatments, extending the lives of patients.

The future of brain cancer treatment

Current standards of care for treating brain cancers – radiation or chemotherapy – primarily kill cancer cells by damaging the DNA of rapidly dividing cancer cells.

When combined with the DDR blocking activity of Patrys deoxymabs, there is potential to significantly increase the efficacy of established therapies.

Funding from the Cure Brain Cancer Foundation will be used for research on Patrys’ PAT-DX1 and PAT-DX3 deoxymabs in in vitro and in vivo models of high-grade glioma (HGG), combining the deoxymabs with standard treatments of care (SOC) such as radiotherapy and temozolomide.

Patrys, a therapeutic antibody development company, believes that adding PAT-DX1 or PAT-DX3 to SOC treatments could significantly increase efficacy by blocking the repair of damaged DNA, which will lead to increased death of cancer cells.

Learn more about HGG

HGG is the most common and deadliest type of brain cancer. Adult patients have only a 10% five-year survival rate with standard treatment (surgical resection, radiotherapy and chemotherapy). In children, HGG is a rapid and universally fatal disease.

HGG tumors grow rapidly and spread quickly through brain tissue, making them very difficult to treat.

Cure Brain Cancer Foundation CEO Lance Kawaguchi said it was an important step towards the goal of improving the quality of life for people living with the disease.

“The Cure Brain Cancer Foundation is honored to award our first-ever Clinical Accelerator to Professor Terry Johns of the Telethon Kids Cancer Center, in collaboration with Australian biotech company Patrys, to further our shared goal of improving treatments for people , especially children, living with brain cancer.

“Having a breakthrough antibody that can potentially be in the clinic by 2023 is life changing, and we are committed to advancing research with rapid results.

“Our mission is to move towards a future where there is a cure for brain cancer and this is a bold step in the right direction. We must continue to support early-stage biotechs like Patrys, to bridge the gap in bringing new therapies to patients.

Comments are closed.